Leading the way with gamma delta T cells

TC BioPharm's mission is to develop and commercialise innovative cell-based products to target disease, improving patient health and Quality of Life

TC BioPharm's mission is to develop and commercialise innovative cell-based products to target disease, improving patient health and Quality of Life

TC BioPharm's mission is to develop and commercialise innovative cell-based products to target disease, improving patient health and Quality of Life

To treat cancer and viral disease

We are currently developing the next generation of safe CAR-T products based on our patent protected, proprietary processes using the clinically proven ImmuniCELL backbone

We are currently developing the next generation of safe CAR-T products based on our patent protected, proprietary processes using the clinically proven ImmuniCELL backbone

We are currently developing the next generation of safe CAR-T products based on our patent protected, proprietary processes using the clinically proven GDT backbone

Improving patient health and Quality of Life
previous arrow
next arrow
Slider

TC BioPharm extends space at Maxim Park

TC BioPharm extends space at Maxim Park

TC BioPharm extends space at Maxim Park

18 MAR 2019

Immunotherapy Company TC BioPharm partners with Trinity College Dublin to develop V delta 1 γδ T cell-based cancer treatments

Immunotherapy Company TC BioPharm partners with Trinity College Dublin to develop V delta 1 γδ T cell-based cancer treatments

Immunotherapy Company TC BioPharm partners with Trinity College Dublin to develop V delta 1 γδ T cell-based cancer treatments

25 FEB 2019

TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products

TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products

TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products

22 JAN 2019

TC BioPharm to present at CAR-TCR Summit, Boston

4 - 7 Sep 2018

TC BioPharm Announces Strategic Collaboration with Scotia Biologics

8 May 2018

TC BioPharm wins Life Sciences Company of the Year 2018

27 April 2018

TC BioPharm Opens First Overseas Office in Japan

14 FEB 2018

TC BioPharm Announces Strategic Collaboration with the NIPRO Corporation

7 FEB 2018

TC BioPharm Announces Strategic Collaboration with bluebird bio

7 Dec 2017

TC BioPharm Announces CAR-T Licensing Deal With UCL Business

6 Sep 2017

TCB Selected For EU Horizon 2020 Funding to Progress Novel, Mass-Market Cell Therapies to Clinical Trial

2 Aug 2017

TCB wins Entrepreneurial Business Leadership Award

2 Feb 2017

TCB raises over £6m for innovative cancer treatments

31 Jan 2017

previous arrow
next arrow
1
2
3
4
5
6
7
8
9
10
11
12
13
Slider

Our vision is to make CAR-T a mainstream therapy for eradicating cancer.

We are developing safer, cheaper, consistent and durable CAR-T drugs for hematological and solid tumors which can be delivered from inventory to outpatients at local clinics as a front-line treatment.

At TC BioPharm we are building on the transformational clinical results of the early CAR-T pioneers using the core technology platforms we have assembled.

GD T cells

GD T cells

Allogeneic Gamma Delta T Cells

Biobanks

Biobanks

HLA-Typed Cell Banks

Co-stim CAR-T

Co-stim CAR-T

Gamma Delta T Cells Modified with Costimulatory CARs

Integrated Model

Integrated Model
In-house R&D, Quality, Manufacturing and Clinical

We take a deliberate step-wise approach to clinical development, starting in 2016 with an autologous GDT cell therapy to demonstrate safety of the vehicle, allowing initiation of an allogeneic GDT cell therapy trial in 2018. Our development focus is on augmenting this ideal vehicle with a proprietary genetic armory to fight a range of cancer diseases.

Our driving vision of developing cures for cancer is a massive challenge and we can’t do it on our own so we work with partners around the world who share our passion for bringing CAR-T therapies to as many patients as possible.

Search